Summary
The non-stimulant cardioselective beta adrenocepter antagonist atenolol has been studied in volunteers in order to define its pharmacokinetic characteristics. Atenolol (100 and 200 mg orally) is rapidly absorbed, reductions in heart rate and systolic pressure being observed in 30 min. The effect persists for up to 8 h. Over 85% of an intravenous dose is excreted in urine within 24 h but only 50% of an oral dose. The bioavailability of approximately 50% is due to reduced absorption. Peak blood levels are observed at 2–4 h and the half life of atenolol given orally is 5–6 h. Atenolol reduces the cardiac response to standing and head-up tilt. It does not reduce circulating levels of renin but slightly impairs the renin response to tilt. Atenolol both orally and intravenously reduces supine diastolic pressure about four hours after administration, the effect persisting for up to 24 h.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barrett, A.M., Carter, J., Fitzgerald, J.D., Hull, R., LeCount, D.: A new type of cardioselective adrenoceptive blocking drug. Brit. J. Pharmacol. Chemother.48, 340 (1973)
Harms, H.A.: Isoproterenol antagonism of cardioselective beta adrenergic receptor blocking agents: A comparative study of human and guinea-pig cardiac and bronchial beta adrenergic receptors. J. Pharmacol. Exp. Therap.199, 329–335 (1976)
Douglas-Jones, A.P., Cruickshank, J.M.: Once daily dosing with atenolol in patients with mild or moderate hypertension. Brit. Med. J.1976/1, 990–991
Amery, A., De Plaen, J.F. Lijnen, P., McAinsh, J., Reybrouck, J.: Relationship between the blood level of atenolol and its pharmacological effect. Clin. Pharmacol. Ther.21, 691 (1977)
Conway, F.J., Fitzgerald, J.D., McAinsh, J., Rowlands, D.J., Simpson, W.T.: Human Pharmacokinetic and Pharmacodynamic studies on atenolol (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug. Brit. J. Clin. Pharmacol.3, 267–272 (1976)
Malbica, A., Motson, J.: A new and expedient method for the determination of atenolol (ICI 66,082) in biological samples. Pharmacol. Sci.64, 1992 (1975)
Viol, G.W., Keane, P.M., Speed, J.F., Smith, E.K.M.: Assay of Plasma renin activity using commercially available reagents. Clin. Biochem.5, 251–265
Shand, D.G.: Pharmacokinetic properties of beta-adrenergic receptor blocking drugs. Drugs7, 39–47 (1974)
Brown, H.C., Carruthers, S.G., Johnston, G.D., Kelly, J.G., McAinsh, J., McDevitt, D.G., Shanks, R.G.: Clinical Pharmacological observations on atenolol, a beta-adrenoceptor blocker. Clin. Pharmacol. Ther.20, 524–534 (1976)
Marlin, G.E., Kumana, C.R., Kaye, C.M., Smith, D.M., Turner, P.: An investigation into the cardiac and pulmonay beta adrenoceptor blocking activity of ICI 66,082 in man. Brit. J. Clin. Pharmacol.2, 151–157 (1975)
Reeves, P.R., McAinsh, J., McIntosh, A.D., Winrow, M.J.: Metabolism of atenolol in man. Zenobiotica (in press 1977)
Sassard, J., Pozet, N., McAinsh, J., Legheand, J., Zech, P.: Pharmacokinetics of atenolol in patients with renal impairment. European J. Clin. Pharmacol.12, 175–180 (1977)
Myers, M.G., Lewis, G.R.J., Steiner, J., Dollery, C.T.: Atenolol in essential hypertension. Clin. Pharmacol. Ther.19, 502–507 (1976)
Scales, B., Copsey, P.B.: The gas chromatographic determination of atenolol in biological samples. J. Pharm. Pharmacol.27, 430–433 (1975)
Reeves, P.: personal communication
Myers, M.G., Lewis, P.J., Reid, J.L., Dollary, C.T.: Brian concentration of propranolol in relation to hypotensive effect in the rabbit with observations on brain propranolol levels in man. J. Pharmacol. Exp. Ther.192, 327–335 (1975)
Ueda, H., Koide, D., Iizuka, A., Ito, I.: Haemodynamic effects of beta-adrenergic blocker (propranolol) in tilted position. Jap. Heart J.7, 438–444 (1966)
Robinson, B.F., Epstein, S.E., Beiser, G.T., Braunwald, E.: Control of heart rate by the autonomic nervous system. Studies in man on the inter-relation between baro-receptor mechanisms and exercise. Circulat. Res.19, 400–411 (1966)
Harris, W.S., Schoenfeld, C.D., Wissler, A.M.: Simplified means for detecting adrenergic influences on human left ventricle. J. Clin. Investigation.46, 1704–1710 (1967)
Forsberg, S.A., Johnsson, G.: Haemodynamic effects of propranolol and H56/28 (alprenolol) in man — a comparative study of two beta-adrenergic receptor antagonists. Acta Pharmacol. Toxicol.25, Suppl. 2, 75/83 (1967)
Stenberg, J., Wasir, H., Amery, A., Sannerstedt, R., Werkö, L.: Comparative haemodynamic studies in man of adrenergic beta1 receptor agents without (H93/26 = metoprolol) or with (H87/07) intrinsic sympthomimetic activity. Acta Pharmacol. Toxicol.36, Suppl. 5, 76–84 (1975)
Olsson, S.B., Varnauskas, E.: Duration of beta-receptor blockade after oral administration of LB46. Europ. J. clin. Pharmacol.5, 214–217 (1973)
Fuccella, L.M., Raban, J., Bassini, F., Lattes, E., Mandelli, V.: Effect of two new beta blocking drugs on heart rate and blood pressure during passive tilting in man. Europ. J. clin. Pharmacol.4, 12–17 (1971)
Aberg, H.: Beta-receptors and renin release. New England J. Med.290, 1026 (1974)
Buhler, F.R., Marbet, G., Patel, U., Burkart, F.: Renin suppressive potency for various beta adrenergic blocking agents at supine rest and during upright exercise. Clin. Sci. Mol. Med.48, Suppl. 2, 61S-64S (1975)
Amery, A., Billiet, L., Boel, A., Fagard, R., Reybrouck, D., Willems, J.: Mechanism of hypotensive effect during beta-adrenergic blockade in hypotensive patients. Amer. Heart J.91, 634–642 (1976)
Amery, A., Billiet, L., Fagard, R.: Beta receptors and renin release. New England J. Med.290, 284 (1974)
Amery, A., Fagard, R., Lijnen, P., Reybrouck, T.: Atenolol and plasma renin concentration in hypertensive patients. Postgrad. Med. J.53, Suppl. 3, 116–119 (1977)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fitzgerald, J.D., Ruffin, R., Smedstad, K.G. et al. Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eur J Clin Pharmacol 13, 81–89 (1978). https://doi.org/10.1007/BF00609750
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00609750